Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus plantarum S58
- Development stage
- Preclinical
- Lead developer
- Southwest University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus plantarum S58 (LP.S58) is a probiotic bacterial strain investigated for its potential in managing metabolic disorders, particularly obesity and hyperlipidemia. In preclinical studies, it has demonstrated the ability to attenuate lipid accumulation and weight gain in high-fat diet-fed models, often showing synergistic effects when combined with hull-less barley β-glucan. Its mechanism involves the activation of the AMPK signaling pathway, which subsequently regulates key transcription factors and enzymes involved in lipogenesis (such as PPARγ, SREBP-1c, and FAS) and fatty acid oxidation (such as CPT-1). Additionally, it helps restore gut microbiota balance, improves intestinal barrier function by increasing tight junction protein expression, and reduces systemic inflammation.
- Other names
- Lactiplantibacillus plantarum S58
02
Targets
SREBP-1 / SREBF1 (SREBP-1)SLC7A1 (Cationic amino acid transporter 1)PPARG (Peroxisome proliferator-activated receptor gamma)AMPK (Adenosine monophosphate–activated protein kinase)FASN (Fatty acid synthase)
Beyond the preview
Go deeper on lactobacillus plantarum S58.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus plantarum S58.